Trevena, Inc. Announces Resignation of Scott Applebaum as Chief Legal and Compliance Officer, Senior Vice President of Regulatory Affairs, and Corporate Secretary, Effective August 31, 2021
August 12, 2021 at 01:02 pm
Share
On August 9, 2021, Scott Applebaum, Chief Legal and Compliance Officer, Senior Vice President of Regulatory Affairs, and Corporate Secretary of Trevena, Inc. formally notified the Company of his resignation, effective August 31, 2021. Mr. Applebaum's resignation was not the result of any disagreement with the Company.
Trevena, Inc. is a biopharmaceutical company focused on the development and commercialization of medicines for patients with central nervous system (CNS) disorders. The Company has one approved product in the United States, OLINVYK (oliceridine) injection, indicated in adults for the management of acute pain severe enough to require an intravenous opioid analgesic and for whom alternative treatments are inadequate. The Companyâs pipeline includes three differentiated investigational drug candidates: TRV045 for diabetic neuropathic pain and epilepsy, TRV250 for the acute treatment of migraine and TRV734 for maintenance treatment of opioid use disorder. TRV045 is a novel, highly selective sphingosine-1-phosphate subtype 1 (S1P1) receptor modulator being developed as a potential treatment for acute and chronic neuropathic pain secondary to diabetic peripheral neuropathy. TRV734 is a small molecule G-protein biased ligand of the mu opioid receptor (MOR).
Trevena, Inc. Announces Resignation of Scott Applebaum as Chief Legal and Compliance Officer, Senior Vice President of Regulatory Affairs, and Corporate Secretary, Effective August 31, 2021
TREVENA, INC. 
